Literature DB >> 25798839

LINE-1 induces hTERT and ensures telomere maintenance in tumour cell lines.

T Aschacher1, B Wolf2, F Enzmann2, P Kienzl2, B Messner1, S Sampl3, M Svoboda4, D Mechtcheriakova4,5, K Holzmann3,5, M Bergmann2,5.   

Abstract

A hallmark of cancer cells is an activated telomere maintenance mechanism, which allows prolonged survival of the malignant cells. In more than 80% of tumours, telomeres are elongated by the enzyme telomerase, which adds de novo telomere repeats to the ends of chromosomes. Cancer cells are also characterized by expression of active LINE-1 elements (L1s, long interspersed nuclear elements-1). L1 elements are abundant retrotransposons in the eukaryotic genome that are primarily known for facilitating aberrant recombination. Using L1-knockdown (KD), we show for the first time that L1 is critical for telomere maintenance in telomerase-positive tumour cells. The reduced length of telomeres in the L1-KD-treated cells correlated with an increased rate of telomere dysfunction foci, a reduced expression of shelterin proteins and an increased rate of anaphase bridges. The decreased telomere length was associated with a decreased telomerase activity and decreased telomerase mRNA level; the latter was increased upon L1 overexpression. L1-KD also led to a decrease in mRNA and protein expression of cMyc and KLF-4, two main transcription factors of telomerase and altered mRNA levels of other stem-cell-associated proteins such as CD44 and hMyb, as well as a corresponding reduced growth of spheroids. The KD of KLF-4 or cMyc decreased the level of L1-ORF1 mRNA, suggesting a specific reciprocal regulation with L1. Thus, our findings contribute to the understanding of L1 as a pathogenicity factor in cancer cells. As L1 is only expressed in pathophysiological conditions, L1 now appears to be target in the rational treatment of telomerase-positive cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25798839     DOI: 10.1038/onc.2015.65

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  81 in total

1.  Transient expression of wild-type or biologically inactive telomerase allows the formation of artificial telomeres in mortal human cells.

Authors:  C Guiducci; M Anglana; A Wang; S Bacchetti
Journal:  Exp Cell Res       Date:  2001-05-01       Impact factor: 3.905

2.  How shelterin solves the telomere end-protection problem.

Authors:  T de Lange
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2011-01-05

3.  Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT).

Authors:  S Kyo; M Takakura; T Taira; T Kanaya; H Itoh; M Yutsudo; H Ariga; M Inoue
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

4.  Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition.

Authors:  Q Feng; J V Moran; H H Kazazian; J D Boeke
Journal:  Cell       Date:  1996-11-29       Impact factor: 41.582

5.  The absence of the dna-dependent protein kinase catalytic subunit in mice results in anaphase bridges and in increased telomeric fusions with normal telomere length and G-strand overhang.

Authors:  F A Goytisolo; E Samper; S Edmonson; G E Taccioli; M A Blasco
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

6.  Reverse transcriptase motifs in the catalytic subunit of telomerase.

Authors:  J Lingner; T R Hughes; A Shevchenko; M Mann; V Lundblad; T R Cech
Journal:  Science       Date:  1997-04-25       Impact factor: 47.728

7.  Phosphorylation of H2AX at short telomeres in T cells and fibroblasts.

Authors:  Ling-Yang Hao; Margaret A Strong; Carol W Greider
Journal:  J Biol Chem       Date:  2004-08-17       Impact factor: 5.157

8.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

Review 9.  Telomerase and cancer therapeutics.

Authors:  Calvin B Harley
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

10.  Onset of quiescence following p53 mediated down-regulation of H2AX in normal cells.

Authors:  Yuko Atsumi; Hiroaki Fujimori; Hirokazu Fukuda; Aki Inase; Keitaro Shinohe; Yoshiko Yoshioka; Mima Shikanai; Yosuke Ichijima; Junya Unno; Shuki Mizutani; Naoto Tsuchiya; Yoshitaka Hippo; Hitoshi Nakagama; Mitsuko Masutani; Hirobumi Teraoka; Ken-ichi Yoshioka
Journal:  PLoS One       Date:  2011-08-12       Impact factor: 3.240

View more
  24 in total

1.  Retrotransposons and genetic instability in hepatocellular carcinoma.

Authors:  Ruchi Shukla
Journal:  Hepat Oncol       Date:  2017-07-18

2.  Cancer gene therapy by NF-κB-activated cancer cell-specific expression of CRISPR/Cas9 targeting telomeres.

Authors:  Wei Dai; Jian Wu; Danyang Wang; Jinke Wang
Journal:  Gene Ther       Date:  2020-02-07       Impact factor: 5.250

3.  Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant TERT promoter methylation, but not hot-spot mutations.

Authors:  Omid Fotouhi; Mehran Ghaderi; Na Wang; Jan Zedenius; Magnus Kjellman; Dawei Xu; C Christofer Juhlin; Catharina Larsson
Journal:  Epigenetics       Date:  2019-07-19       Impact factor: 4.528

Review 4.  Telomerase gene therapy: a remission toward cancer.

Authors:  Sameer Quazi
Journal:  Med Oncol       Date:  2022-04-16       Impact factor: 3.064

Review 5.  RNA as a fundamental component of interphase chromosomes: could repeats prove key?

Authors:  Lisa L Hall; Jeanne B Lawrence
Journal:  Curr Opin Genet Dev       Date:  2016-05-21       Impact factor: 5.578

6.  High levels of LINE-1 transposable elements expressed in Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma.

Authors:  Anuj Ahuja; Guy Journo; Ron Eitan; Eitan Rubin; Meir Shamay
Journal:  Oncogene       Date:  2020-11-13       Impact factor: 9.867

Review 7.  The Reverse Transcriptase Encoded by LINE-1 Retrotransposons in the Genesis, Progression, and Therapy of Cancer.

Authors:  Ilaria Sciamanna; Chiara De Luca; Corrado Spadafora
Journal:  Front Chem       Date:  2016-02-11       Impact factor: 5.221

Review 8.  Crossing the LINE Toward Genomic Instability: LINE-1 Retrotransposition in Cancer.

Authors:  Jacqueline R Kemp; Michelle S Longworth
Journal:  Front Chem       Date:  2015-12-16       Impact factor: 5.221

Review 9.  Guardian of the Human Genome: Host Defense Mechanisms against LINE-1 Retrotransposition.

Authors:  Yasuo Ariumi
Journal:  Front Chem       Date:  2016-06-28       Impact factor: 5.221

10.  Association between Long Interspersed Nuclear Element-1 Methylation and Relative Telomere Length in Wilms Tumor.

Authors:  Hui-Bo Chang; Ji-Zhen Zou; Cai He; Rui Zeng; Yuan-Yuan Li; Fei-Fei Ma; Zhuo Liu; Hui Ye; Jian-Xin Wu
Journal:  Chin Med J (Engl)       Date:  2015-11-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.